Low Molecular Weight Heparin (Reviparin) in Percutaneous Transluminal Coronary Angioplasty - REDUCE

Description:

REDUCE was a prospective, randomized, double-blind trial of the low molecular weight heparin (LMWH) reviparin versus unfractionated heparin (UFH) for prevention of adverse events and restenosis in patients with coronary artery disease undergoing percutaneous transluminal coronary angioplasty (PTCA).